Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer

Exclusion Criteria

• •Patients who are currently receiving and responding to a different course of anti-neoplastic therapy, within the limits of acceptable toxicity per standard clinical practice, may not be enrolled to this study
• •Current symptomatic brain metastases. If previously present, the metastases must have been treated at least two months before participation in this study. CT or MRI scan of the brain is mandatory to assess the presence or not of brain metastases
• •History of other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or basal cell, or squamous cell carcinoma of the skin
• •History of significant cardiac disease defined as:
• •* Symptomatic CHF (NYHA classes III-IV)
• •* High-risk uncontrolled arrhythmias; i.e. atrial tachycardia with a heart rate \> 100/min at rest, significant ventricular arrhythmia or higher-grade AV-block (second degree AV-block Type 2 \[Mobitz 2\] or third degree AV-block)
• •* Prolongation of QT interval \> 480 msecs
• •* History of myocardial infarction within last 12 months
• •* Clinically significant valvular heart disease
• •* Angina pectoris requiring anti-angina treatment
• •* Current uncontrolled hypertension (persistent systolic \> 180 mmHg and/or diastolic \> 100 mmHg). Initiation or adjustment of antihypertensive medication is permitted prior to study entry
• •Evidence of active bleeding or bleeding diathesis
• •Cerebrovascular accident at any time in the past, transient ischemic attack, deep venous thrombosis or pulmonary embolism in the past 6 months
• •Current severe, uncontrolled systemic disease
• •Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
• •Failure to use contraception in patients with preserved reproductive capacity